Currently out of the existing stock ratings of Robert Burns, 612 are a BUY (90.94%), 61 are a HOLD (9.06%).

Robert Burns

Work Performance Price Targets & Ratings Chart

Analyst Robert Burns, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 32.87% that have a potential upside of 39.95% achieved within 128 days.

Robert Burns’s has documented 1,291 price targets and ratings displayed on 57 stocks. The coverage is on Healthcare, Basic Materials, Technology sectors.

Most recent stock forecast was given on PMVP, Pmv Pharmaceuticals at 03-Sep-2026.

Wall Street Analyst Robert Burns

Analyst best performing recommendations are on COGT (COGENT BIOSCIENCES).
The best stock recommendation documented was for COGT (COGENT BIOSCIENCES) at 11/4/2025. The price target of $21 was fulfilled within 6 days with a profit of $6.87 (48.62%) receiving and performance score of 81.03.

Average potential price target upside

of $350 (123.2%) on ATRA (ATARA BIOTHERAPEUTICS).
of $133.96 (95.98%) on CLDI (CALIDI BIOTHERAPEUTICS).
of $82.15 (81.88%) on PRTG (PORTAGE BIOTECH).

AADI Aadi Bioscience BNTX BioNTech SE CRBU Caribou Biosciences CTMX CytomX Therapeutics FATE Fate Therapeutics IGMS IGM Biosciences MGNX MacroGenics NRIX Nurix Therapeutics NUVB Nuvation Bio ORIC Oric Pharmaceuticals RLAY Relay Therapeutics RPTX Repare Therapeutics RVMD Revolution Medicines ADCT ADC Therapeutics SA IKNA Ikena Oncology KRON Kronos Bio NCNA NuCana PLC PRTG Portage Biotech TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics ZYME Zymeworks Common Stock SWTX SpringWorks Therapeutics NLTX Neoleukin Therapeutics PRLD Prelude Therapeutics YMAB Y mAbs Therapeutics ATRA Atara Biotherapeutics GTBP GT Biopharma KNTE Kinnate Biopharma OMGA Omega Therapeutics PMVP Pmv Pharmaceuticals REPL Replimune Group TNGX Tango Therapeutics ALLO Allogene Therapeutics BDTX Black Diamond Therapeutics COGT Cogent Biosciences VIRX Viracta Therapeutics AUTL Autolus Therapeutics Ltd FMTX Forma Therapeutics Holdings EXEL Exelixis AVBP ArriVent BioPharma, Common Stock BCAX Bicara Therapeutics Common Stock CRGX CARGO Therapeutics, Common Stock ELVN Enliven Therapeutics OKUR OnKure Therapeutics CGEM Cullinan Oncology LLC CRDF Cardiff Oncology KPTI Karyopharm Therapeutics ACET Adicet Bio MOLN Molecular Partners AG ADR CATX Perspective Therapeutics BOLT Bolt Biotherapeutics KRO Kronos Worldwide RPT RPT Realty TLX Telix Pharmaceuticals SW Smurfit WestRock plc AKTS Akoustis Technologies CLDI Calidi Biotherapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Joseph Catanzaro (MIZUHO)

Buy Since 08-Sep-2021

$1.75

$-0.27 (-13.37%)

2 years 14 days ago
(27-Aug-2024)

1/4 (25%)

$0.07 (4.17%)

Roger Song (JEFFERIES)

Buy Since 12-Jan-2022

$1.5

$-0.52 (-25.74%)

2 years 20 days ago
(21-Aug-2024)

0/2 (0%)

$-0.05 (-3.23%)

Robert Burns (HC WAINWRIGHT)

Hold Since 14-May-2024

2 years 20 days ago
(21-Aug-2024)

0/4 (0%)

$31.56 (191.97%)

Raghuram Selvaraju (HC WAINWRIGHT)

Buy Since 30-Aug-2021

$48

$45.98 (2276.24%)

$49

4 years 4 months 30 days ago
(11-Apr-2022)

0/3 (0%)

$31.56 (191.97%)

Yi Chen (HC WAINWRIGHT)

Buy Since 30-Aug-2021

$48

$45.98 (2276.24%)

$49

4 years 4 months 30 days ago
(11-Apr-2022)

1/4 (25%)

$31.56 (191.97%)

117

Show more analysts

Please expand the browser size to see the chart

Which stock is Robert Burns most bullish on?

Potential upside of $72.32 has been obtained for RVMD (REVOLUTION MEDICINES)

Which stock is Robert Burns most reserved on?

Potential downside of -$3.01 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Robert Burns?

On 2019